KOJECKÝ, Vladimír, Jan MATOUS, Bohuslav KIANIČKA, Petr DITE, Zdena ZADOROVA, Jan KUBOVY, Martina HLOSTOVA a Michal UHER. Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. ABINGDON: TAYLOR & FRANCIS LTD, 2020, roč. 55, č. 6, s. 671-676. ISSN 0036-5521. Dostupné z: https://dx.doi.org/10.1080/00365521.2020.1774921.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation
Autoři KOJECKÝ, Vladimír (203 Česká republika, domácí), Jan MATOUS (203 Česká republika), Bohuslav KIANIČKA (203 Česká republika, garant), Petr DITE (203 Česká republika), Zdena ZADOROVA (203 Česká republika), Jan KUBOVY (203 Česká republika), Martina HLOSTOVA (203 Česká republika) a Michal UHER (203 Česká republika, domácí).
Vydání SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, ABINGDON, TAYLOR & FRANCIS LTD, 2020, 0036-5521.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30219 Gastroenterology and hepatology
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.423
Kód RIV RIV/00216224:14110/20:00116133
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1080/00365521.2020.1774921
UT WoS 000545392100001
Klíčová slova anglicky Inflammatory bowel disease; vitamin D deficiency; vitamin D intake; dietary supplements; body weight
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 31. 8. 2020 10:43.
Anotace
Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.
VytisknoutZobrazeno: 13. 7. 2024 13:59